Relay Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Relay Therapeutics, Inc. (RLAY), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are RLAY insiders buying or selling?
In the last 12 months, Relay Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 32 sales ($130.2M) — net selling of $130.2M. Since July 2020, Trabud has recorded 202 Form 4 filings for RLAY: 5 buys ($2.2M) and 197 sells ($389.9M).
Source: SEC EDGAR Form 4
What stands out
- No Relay Therapeutics, Inc. insider made an open-market purchase in the last 12 months; the 32 reported open-market sales totaled $130.2M.
Key Statistics (July 2020 – Oct 8, 2026)
Total Form 4 filings
202
SEC EDGAR
Insider filers
11
Insider buys (5)
$2.2M
Insider sells (197)
$389.9M
Insider sentiment
Net sellingNet insider flow of $387.7M in net selling since July 2020, and $130.2M in net selling over the last 12 months.
Recent RLAY insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | Sanjiv Patel | President and CEO | Sale | 48.2K | $18.10 | $872.4K | SEC ↗ |
| Oct 8, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 17.7K | $18.59 | $329.3K | SEC ↗ |
| Sep 9, 2026 | Donald A Bergstrom | President, R&D | Sale | 8.5K | $18.97 | $161.8K | SEC ↗ |
| Sep 9, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 17.7K | $18.94 | $335.6K | SEC ↗ |
| Sep 9, 2026 | Sanjiv Patel | President and CEO | Sale | 48.2K | $18.94 | $912.9K | SEC ↗ |
| Aug 28, 2026 | Peter Rahmer | Chief Corporate Development Officer | Sale | 4.5K | $20.03 | $90.3K | SEC ↗ |
| Aug 28, 2026 | SVF Pauling (Cayman) Ltd | 10% Owner | Sale | 6.0M | $19.40 | $116.4M | SEC ↗ |
| Aug 18, 2026 | Sanjiv Patel | President and CEO | Sale | 48.2K | $20.33 | $979.9K | SEC ↗ |
| Aug 18, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 17.7K | $19.74 | $349.7K | SEC ↗ |
| Jul 30, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 1.5K | $18.61 | $27.2K | SEC ↗ |
| Jul 30, 2026 | Peter Rahmer | Cheif Corporate Development Officer | Sale | 748 | $18.61 | $13.9K | SEC ↗ |
| Jul 30, 2026 | Donald A Bergstrom | President, R&D | Sale | 2.2K | $18.61 | $41.6K | SEC ↗ |
| Jul 8, 2026 | Donald A Bergstrom | President, R&D | Sale | 8.7K | $18.71 | $162.0K | SEC ↗ |
| Jul 8, 2026 | Sanjiv Patel | President and CEO | Sale | 48.2K | $19.58 | $943.7K | SEC ↗ |
| Jul 8, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 17.7K | $18.69 | $331.1K | SEC ↗ |
| Jul 2, 2026 | Peter Rahmer | Chief Corporate Development Officer | Sale | 50.0K | $19.09 | $954.5K | SEC ↗ |
| Jun 24, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 187.2K | $16.97 | $3.2M | SEC ↗ |
| Jun 24, 2026 | Donald A Bergstrom | President, R&D | Sale | 93.5K | $16.94 | $1.6M | SEC ↗ |
| May 14, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 17.7K | $12.86 | $227.8K | SEC ↗ |
| Apr 30, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 972 | $14.79 | $14.4K | SEC ↗ |
| Apr 30, 2026 | Peter Rahmer | Chief Corporate Development Officer | Sale | 753 | $14.79 | $11.1K | SEC ↗ |
| Apr 30, 2026 | Donald A Bergstrom | President, R&D | Sale | 1.5K | $14.79 | $22.0K | SEC ↗ |
| Apr 10, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 19.5K | $13.19 | $257.5K | SEC ↗ |
| Mar 11, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 17.7K | $10.06 | $178.2K | SEC ↗ |
| Jan 29, 2026 | Donald A Bergstrom | President, R&D | Sale | 21.6K | $7.72 | $166.7K | SEC ↗ |
Showing the 25 most recent of 202 Form 4 filings for Relay Therapeutics, Inc..
Most active RLAY insiders
- Donald A Bergstrom53 filings
- Thomas Catinazzo50 filings
- Brian Adams38 filings
- Peter Rahmer29 filings
- Sanjiv Patel19 filings
Ask anything about RLAY insider activity
Use Trabud's AI agent to query Relay Therapeutics, Inc.'s Form 4 history in plain English — "Show me RLAY CEO purchases this year" or compare it against any other ticker.
Open the AI agentRLAY insider trading FAQ
Are Relay Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Relay Therapeutics, Inc. insiders reported 0 open-market purchases ($0) and 32 sales ($130.2M) — net selling of $130.2M. Since July 2020, Trabud has recorded 202 Form 4 filings for RLAY: 5 buys ($2.2M) and 197 sells ($389.9M). Over the full record that is net selling of $387.7M.
How many insiders trade RLAY stock?
11 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Relay Therapeutics, Inc.. The most recent filing was accepted on Oct 8, 2026.
Where does Trabud get RLAY insider trading data?
All RLAY insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.